TAKHZYRO® (lanadelumab), the first approved monoclonal antibody for the treatment of HAE, has been named the 2022 winner of the prestigious Prix Galien Canada Innovative Product Award. The most prestigious award in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements of pharmaceutical research and development.
“We are honored TAKHZYRO has received the Prix Galien Canada 2022 Innovative Product Award, and are even more proud of the tremendous impact it’s had on HAE patients in Canada,” says Rute Fernandes, General Manager of Takeda Canada Inc. “This prestigious award is a reflection of Takeda’s dedication and commitment to bring innovative treatments to patients.”
(Source: Takeda)
